



Accredited by  
Joint Commission International

# Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



Indraprastha  
**Apollo**  
HOSPITALS  
TOUCHING LIVES

**A. K. SINGHAL**  
Vice President  
Cum Company Secretary

Ref.: IMCL/CS/BSE/BM/2018

7<sup>th</sup> February, 2018

The BSE Ltd.,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

## Stock Code 532150

Sub.: Unaudited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2017

Dear Sir,

Enclosed please find a copy of the Unaudited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2017, along with a copy of the Limited Review Report by the Auditors.

The Board meeting ended at 4.55 p.m..

This is for your information and record.

Thanking You,

Sincerely Yours,

  
A.K.SINGHAL

Encl. as above

Statement of Unaudited Financial Results for the Quarter and Nine-months ended 31<sup>st</sup> December, 2017


| S. No. | Particulars   | Amount (Rs. in Lacs)      |                           |                           |                           |                           |                         |
|--------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
|        |   | Quarter ended             |                           |                           | Nine-months               |                           | Financial               |
|        |   | 31.12.2017<br>(Unaudited) | 30.09.2017<br>(Unaudited) | 31.12.2016<br>(Unaudited) | 31.12.2017<br>(Unaudited) | 31.12.2016<br>(Unaudited) | 31.03.2017<br>(Audited) |
| 1      | Revenue from operations   | 18408.57                  | 19098.37                  | 19074.53                  | 55930.45                  | 57796.95                  | 76571.62                |
| 2      | Other Income  | 54.06                     | 9.83                      | 20.09                     | 72.59                     | 35.70                     | 159.26                  |
| 3      | Total income  | 18462.63                  | 19108.20                  | 19094.62                  | 56003.04                  | 57832.65                  | 76730.88                |
| 4      | Expenses  |                           |                           |                           |                           |                           |                         |
|        | a) Cost of material consumed  | 3359.90                   | 3629.24                   | 3786.89                   | 10578.56                  | 11385.62                  | 15021.28                |
|        | b) Purchase of stock in trade   | -                         | -                         | -                         | -                         | -                         | -                       |
|        | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade  | -                         | -                         | -                         | -                         | -                         | -                       |
|        | d) Employee benefits expense  | 4811.10                   | 4830.45                   | 4823.20                   | 14265.16                  | 14159.34                  | 19025.71                |
|        | e) Consultation fee paid to Doctors   | 4652.75                   | 4933.25                   | 4809.36                   | 14381.92                  | 14533.19                  | 19145.51                |
|        | f) Finance cost   | 239.89                    | 230.27                    | 209.02                    | 682.37                    | 568.79                    | 790.54                  |
|        | g) Depreciation and amortisation expense  | 773.14                    | 777.38                    | 753.62                    | 2309.32                   | 2227.00                   | 3053.21                 |
|        | h) Other expenses   | 3789.83                   | 3894.01                   | 3791.99                   | 11407.63                  | 11622.05                  | 15612.87                |
|        | Total expenses  | 17626.61                  | 18294.60                  | 18174.08                  | 53624.96                  | 54495.99                  | 72649.12                |
| 5      | Profit before exceptional items and tax   | 836.02                    | 813.60                    | 920.54                    | 2378.08                   | 3336.66                   | 4081.76                 |
| 6      | Exceptional items   | -                         | -                         | -                         | -                         | -                         | -                       |
| 7      | Profit before tax (PBT)   | 836.02                    | 813.60                    | 920.54                    | 2378.08                   | 3336.66                   | 4081.76                 |
| 8      | Tax expense   |                           |                           |                           |                           |                           |                         |
|        | Current tax   | 174.60                    | 293.78                    | 424.41                    | 783.94                    | 1382.30                   | 1854.11                 |
|        | Deferred tax  | 109.71                    | (4.61)                    | (104.14)                  | 42.05                     | (202.04)                  | (396.88)                |
| 9      | Profit for the period after tax (PAT)   | 551.71                    | 524.43                    | 600.27                    | 1552.09                   | 2156.40                   | 2624.53                 |
| 10     | Other comprehensive income  |                           |                           |                           |                           |                           |                         |
|        | a). (i) Items that will not be reclassified to profit or loss                     | 45.00                     | 24.12                     | 116.83                    | 76.55                     | 40.58                     | 106.14                  |
|        | (ii) Income Tax relating to items that will not be reclassified to profit or loss | (15.57)                   | (8.35)                    | (40.43)                   | (26.49)                   | (14.04)                   | (36.73)                 |
|        | Total other comprehensive income, Net of tax expenses                             | 29.43                     | 15.77                     | 76.40                     | 50.06                     | 26.54                     | 69.41                   |
| 11     | Total comprehensive income for the period   | 581.14                    | 540.20                    | 676.67                    | 1602.15                   | 2182.94                   | 2693.94                 |
| 12     | Paid-up equity share capital (Face value Rs. 10/- each)                           | 9167.30                   | 9167.30                   | 9167.30                   | 9167.30                   | 9167.30                   | 9167.30                 |
| 13     | Earnings per share Basic and Diluted (Rs.)  | 0.60                      | 0.57                      | 0.65                      | 1.69                      | 2.35                      | 2.86                    |

**Notes:**

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 7<sup>th</sup> February, 2018.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Statutory Auditors have carried out a Limited review of the financial results for the quarter and nine-months ended 31<sup>st</sup> December, 2017.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi  
Date : 7<sup>th</sup> February, 2018



  
Ashok Bajpai  
Managing Director

## **Limited Review Report On Quarterly Financial Results and Year to Date Results of the Indraprastha Medical Corporation Limited Pursuant to the Regulation 33 of the SEBI (LODR) Regulations, 2015**

### **To The Board of Directors of Indraprastha Medical Corporation Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter ended 31 December 2017 and the year to-date results for the period 01 April 2017 to 31 December 2017 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements (LODR)) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of Companies (Ind AS) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



The comparative Ind AS financial information of the Company for the corresponding quarter 31 December 2016, the corresponding year to date results for the period 01 April 2016 to 31 December 2016 were reviewed by the predecessor auditor and the Ind AS financial statements of the Company for the year ended 31 March 2017 were audited by predecessor auditor who expressed an unmodified opinion on those financial information and financial statements on 30 January 2017 and 26 May 2017 respectively. Our opinion is not modified in respect of this matter.

For **S.N. Dhawan & Co LLP**  
(Formerly S. N. Dhawan & Co.)

Chartered Accountants

Firm Registration No.: 000050N/N500045



**Rajeev K Saxena**

Partner

Membership No.: 077974

Date: February 07, 2018

Place: New Delhi